Published Online
on March 1, 2004

A more recent version of this article appeared on March 23, 2004

This Article Full Text (PDF) All Versions of this Article: 109/11/1386    most recent 01.CIR.0000120703.99433.1Ev1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Whang, W. Search for Related Content PubMed PubMed Citation Articles by Whang, W. Pubmed/NCBI databases Medline Plus Health Information Heart Failure Pacemakers and Implantable Defibrillators Related Collections Congestive Ablation/ICD/surgery Arrhythmias, clinical electrophysiology, drugs

Submitted on August 22, 2003
Revised on October 30, 2003
Accepted on January 5, 2004

Heart Failure and the Risk of Shocks in Patients With Implantable Cardioverter Defibrillators. Results From the Triggers Of Ventricular Arrhythmias (TOVA) Study

William Whang MD, MS^*, Murray A. Mittleman MD, DrPH, David Q. Rich MPH, Paul J. Wang MD, Jeremy N. Ruskin MD, Geoffrey H. Tofler MD, James E. Muller MD, Christine M. Albert MD, MPH, and for the TOVA Investigators

From the Cardiovascular Division, (W.W., J.N.R., J.E.M., C.M.A.) Massachusetts General Hospital, Cardiovascular Division (D.Q.R., M.A.M.), Beth Israel Deaconess Medical Center, and the Division of Preventive Medicine (C.M.A.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; Stanford University Medical Center (P.J.W.), Stanford, Calif; and the Royal North Shore Hospital (G.E.H.), Sydney, Australia.

^* To whom correspondence should be addressed. E-mail: wwhang{at}partners.org.

Background--Left ventricular ejection fraction (LVEF) predicts device discharges in patients with implantable cardioverter-defibrillators (ICDs). The relationship between severity of congestive heart failure (CHF) and ICD discharges is less clear.

Methods and Results--We prospectively analyzed the association between CHF and risk of appropriate ICD discharges in the Triggers Of Ventricular Arrhythmias (TOVA) study, a cohort study of ICD patients conducted at 31 centers in the United States. Reported shocks were confirmed for sustained ventricular tachycardia (VT) or fibrillation (VF) by analysis of stored electrograms. Proportional hazards models included CHF categorized by New York Heart Association class. Baseline CHF was present among 502 (44%) of 1140 patients; 170 (34%) had class I, 230 (46%) had class II, 97 (19%) had class III, and only 5 (1%) had class IV symptoms. During median follow-up of 212 days, 92 patients experienced 1 or more appropriate ICD discharges. Class III CHF was associated in a statistically significantly manner with ICD discharge for VT/VF (hazard ratio 2.40, 95% CI 1.16 to 4.98), even with adjustment for LVEF. The combination of LVEF <0.20 and class III symptoms resulted in a particularly high risk of shocks for VT/VF (hazard ratio 3.90, 95% CI 1.28 to 11.92).

Conclusions--Class III CHF, an easily accessible clinical measure, is an independent risk factor, along with LVEF, for ventricular arrhythmias that require shock therapy among ICD patients. Whether patients with class III CHF benefit to a greater degree from ICDs and whether aggressive treatment of CHF in ICD patients may prevent ventricular arrhythmias remains to be determined.

Key words: heart failure • tachyarrhythmias • defibrillation • cardioversion

This article has been cited by other articles:

				J. D. Mishkin, S. J. Saxonhouse, G. W. Woo, T. A. Burkart, W. M. Miles, J. B. Conti, R. S. Schofield, S. F. Sears, and J. M. Aranda Jr Appropriate Evaluation and Treatment of Heart Failure Patients After Implantable Cardioverter-Defibrillator Discharge Time to Go Beyond the Initial Shock. J. Am. Coll. Cardiol., November 24, 2009; 54(22): 1993 - 2000. [Abstract] [Full Text] [PDF]

				E. M. Kanoupakis, E. G. Manios, and P. E. Vardas Predicting future shocks in implantable cardioverter defibrillator recipients: the role of biomarkers Europace, November 1, 2009; 11(11): 1434 - 1439. [Abstract] [Full Text] [PDF]

				K. C. van den Broek, I. Nyklicek, P. H. van der Voort, M. Alings, A. Meijer, and J. Denollet Risk of ventricular arrhythmia after implantable defibrillator treatment in anxious type D patients. J. Am. Coll. Cardiol., August 4, 2009; 54(6): 531 - 537. [Abstract] [Full Text] [PDF]

				D. D. Matlock, R. M. Telerant, N. Boyer, D. Kansagara, R. Passman, A. Kadish, S. Sears, and D. B. Mark Defibrillators in Heart Failure and Quality of Life N. Engl. J. Med., January 8, 2009; 360(2): 187 - 189. [Full Text] [PDF]

				J. J. Goldberger, M. E. Cain, S. H. Hohnloser, A. H. Kadish, B. P. Knight, M. S. Lauer, B. J. Maron, R. L. Page, R. S. Passman, D. Siscovick, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death: A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1179 - 1199. [Full Text] [PDF]

				J. J. Goldberger, M. E. Cain, S. H. Hohnloser, A. H. Kadish, B. P. Knight, M. S. Lauer, B. J. Maron, R. L. Page, R. S. Passman, D. Siscovick, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death: A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention Circulation, September 30, 2008; 118(14): 1497 - 1518. [Full Text] [PDF]

				M. T. Koller, B. Schaer, M. Wolbers, C. Sticherling, H. C. Bucher, and S. Osswald Death Without Prior Appropriate Implantable Cardioverter-Defibrillator Therapy: A Competing Risk Study Circulation, April 15, 2008; 117(15): 1918 - 1926. [Abstract] [Full Text] [PDF]

				A. Gardiwal, H. Yu, H. Oswald, U. Luesebrink, A. Ludwig, A. M. Pichlmaier, H. Drexler, and G. Klein Right ventricular pacing is an independent predictor for ventricular tachycardia/ventricular fibrillation occurrence and heart failure events in patients with an implantable cardioverter-defibrillator Europace, March 1, 2008; 10(3): 358 - 363. [Abstract] [Full Text] [PDF]

				C. Bruch, C. Bruch, J. Sindermann, G. Breithardt, and R. Gradaus Prevalence and prognostic impact of comorbidities in heart failure patients with implantable cardioverter defibrillator Europace, August 1, 2007; 9(8): 681 - 686. [Abstract] [Full Text] [PDF]

				H. Nagele, S. Hashagen, M. Azizi, S. Behrens, and M.A. Castel Analysis of terminal arrhythmias stored in the memory of pacemakers from patients dying suddenly Europace, June 1, 2007; 9(6): 380 - 384. [Abstract] [Full Text] [PDF]

				L. A. Saxon, M. R. Bristow, J. Boehmer, S. Krueger, D. A. Kass, T. De Marco, P. Carson, L. DiCarlo, A. M. Feldman, E. Galle, et al. Predictors of Sudden Cardiac Death and Appropriate Shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial Circulation, December 19, 2006; 114(25): 2766 - 2772. [Abstract] [Full Text] [PDF]

				G. H. Tofler and J. E. Muller Triggering of Acute Cardiovascular Disease and Potential Preventive Strategies Circulation, October 24, 2006; 114(17): 1863 - 1872. [Full Text] [PDF]

				G. Klein, C. Lissel, A.-C. Fuchs, A. Gardiwal, H. Oswald, M. deSousa, A. M. Pichlmaier, R. Lichtinghagen, H. Geerlings, P. Lippolt, et al. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study. Europace, August 1, 2006; 8(8): 618 - 624. [Abstract] [Full Text] [PDF]

				J. Gy. Papp, P. Pollesello, A. F. Varro, and A. S. Vegh Effect of Levosimendan and Milrinone on Regional Myocardial Ischemia/Reperfusion-Induced Arrhythmias in Dogs Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2006; 11(2): 129 - 135. [Abstract] [PDF]

				A Verma, F Kilicaslan, D O Martin, S Minor, R Starling, N F Marrouche, S Almahammed, O M Wazni, S Duggal, R Zuzek, et al. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies Heart, February 1, 2006; 92(2): 190 - 195. [Abstract] [Full Text] [PDF]

				J. P. Singh, W. J. Hall, S. McNitt, H. Wang, J. P. Daubert, W. Zareba, J. N. Ruskin, A. J. Moss, and and the MADIT-II Investigators Factors Influencing Appropriate Firing of the Implanted Defibrillator for Ventricular Tachycardia/Fibrillation: Findings From the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1712 - 1720. [Abstract] [Full Text] [PDF]

				S. B. Dunbar Psychosocial Issues of Patients With Implantable Cardioverter Defibrillators Am. J. Crit. Care., July 1, 2005; 14(4): 294 - 303. [Abstract] [Full Text] [PDF]

				W. Whang, C. M. Albert, S. F. Sears Jr, R. Lampert, J. B. Conti, P. J. Wang, J. P. Singh, J. N. Ruskin, J. E. Muller, M. A. Mittleman, et al. Depression as a predictor for appropriate shocks among patients with implantable cardioverter-defibrillators: Results from the Triggers of Ventricular Arrhythmias (TOVA) study J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1090 - 1095. [Abstract] [Full Text] [PDF]

				I. R. Hanna and J. J. Langberg The Shocking Story of Azimilide Circulation, December 14, 2004; 110(24): 3624 - 3626. [Full Text] [PDF]